Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.47 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28379794 | 0.88 | ALDH1A1 (0.46) | — | |
| SCHEMBL11451186 | 0.88 | GBA1 (0.50) | — | |
| Ammonia Solution, Strong SCHEMBL14359739 | 0.86 | GBA1 (0.48) | — | |
| SCHEMBL5987408 | 0.85 | — | — | |
| Ammonia Solution, Strong SCHEMBL4076473 | 0.83 | EPHX2 (0.45) | — | |
| SCHEMBL19835246 | 0.82 | CHRM1 (0.43) | LPAR3LPAR1LPAR2FAAHTRPV1 | |
| SCHEMBL19835262 | 0.82 | CHRM1 (0.43) | LPAR3LPAR1LPAR2FAAHTRPV1 | |
| SCHEMBL19833700 | 0.82 | CHRM1 (0.43) | LPAR3LPAR1LPAR2FAAHTRPV1 | |
| SCHEMBL14366474 | 0.80 | GBA1 (0.38) | — | |
| SCHEMBL17058984 | 0.80 | GBA1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3403650-A2 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Blanchette Rockefeller Neurosciences, Institute (US) | 2018-11-21 | — | — | EP | claimed |
| US-20160060236-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2016-03-03 | — | — | US | claimed |
| US-20120149768-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Blanchette Rockefeller Neurosciences Institute. | 2012-06-14 | — | — | US | claimed |
| JP-2011529503-A | — | — | 2011-12-08 | — | — | JP | claimed |
| WO-2010014585-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2010-02-04 | — | — | WO | claimed |
| US-20100022645-A1 | PKC-Activating Compounds for the Treatment of Neurodegenerative Diseases | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2010-01-28 | — | — | US | claimed |
| US-20240025870-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Synaptogenix, Inc. (US) | 2024-01-25 | — | — | US | disclosed |
| US-11820745-B2 | PKC-activating compounds for the treatment of neurodegenerative diseases | Synaptogenix, Inc. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230235378-A1 | LZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF PROTEIN KINASE C EPSILON (PKC-EPSILON PROTEIN LEVELS | WEST VIRGINIA UNIVERSITY | 2023-07-27 | — | — | US | disclosed |
| US-20220356161-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Synaptogenix, Inc. (US) | 2022-11-10 | — | — | US | disclosed |
| US-11390596-B2 | PKC-activating compounds for the treatment of neurodegenerative diseases | Synaptogenix, Inc. (US) | 2022-07-19 | — | — | US | disclosed |
| US-20200331875-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COGNITIVE RESEARCH ENTERPRISES, INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-10696644-B2 | PKC-activating compounds for the treatment of neurodegenerative diseases | COGNITIVE RESEARCH ENTERPRISES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20120027687-A1 | FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE | WEST VIRGINIA UNIVERSITY | 2012-02-02 | — | — | US | disclosed |
| WO-2012006525-A2 | PKC ACTIVATORS AND ANTICOAGULANT IN REGIMEN FOR TREATING STROKE | ALKON DANIEL L (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2012006510-A1 | FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE | ALKON DANIEL L (US) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011102907-A1 | ALZHEIMER'S DISEASE-SPECIFIC ALTERATIONS OF PROTEIN KINASE C EPSILON (PKC-EPSILON) PROTEIN LEVELS | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2011-08-25 | — | — | WO | disclosed |
| EP-2328572-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Blanchette Rockefeller Neurosciences Institute (US) | 2011-06-08 | — | — | EP | disclosed |
| WO-2010014585-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100022645-A1 | PKC-Activating Compounds for the Treatment of Neurodegenerative Diseases | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060236-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PRKCH, PRKCA, PRKCG | LPAR3 314/4885LPAR1 230/4885LPAR2 193/4885 |
| US-20120149768-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PRKCH, PRKCA, PRKCG | LPAR3 314/4885LPAR1 230/4885LPAR2 193/4885 |
| US-20220356161-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PRKCH, PRKCA, PRKCG | LPAR3 314/4885LPAR1 230/4885LPAR2 193/4885 |
| US-20100022645-A1 | PKC-Activating Compounds for the Treatment of Neurodegenerative Diseases | PRKCH, PRKCA, PRKCG | LPAR3 314/4885LPAR1 230/4885LPAR2 193/4885 |
| US-11820745-B2 | PKC-activating compounds for the treatment of neurodegenerative diseases | PRKCH, PRKCA, PRKCG | LPAR3 314/4885LPAR1 230/4885LPAR2 193/4885 |
| US-20240025870-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PRKCH, PRKCA, PRKCG | LPAR3 294/4885LPAR1 207/4885LPAR2 167/4885 |
| US-20200331875-A1 | PKC-ACTIVATING COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | PRKCH, PRKCA, PRKCG | LPAR3 314/4885LPAR1 230/4885LPAR2 193/4885 |
| US-11390596-B2 | PKC-activating compounds for the treatment of neurodegenerative diseases | PRKCH, PRKCA, PRKCG | LPAR3 314/4885LPAR1 230/4885LPAR2 193/4885 |
| US-20120027687-A1 | FATTY ACID PROTEIN KINASE C ACTIVATORS AND ANTICOAGULANT FOR THE TREATMENT OF STROKE | PRKCA, FABP7, PRKCZ | LPAR3 690/4885LPAR1 544/4885LPAR2 369/4885 |
| US-10696644-B2 | PKC-activating compounds for the treatment of neurodegenerative diseases | PRKCH, PRKCA, PRKCG | LPAR3 314/4885LPAR1 230/4885LPAR2 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.